Get the Stockscreener App
832.58
0.59%
3.74
Overview
News
Price History
Option Chain
Financials
Discussions
Forecast
Stock Split
Dividend History
Mckesson Corp stock is traded at $832.58, with a volume of 44,485.
It is up +0.59% in the last 24 hours and up +11.94% over the past month.
McKesson is one of three leading pharmaceutical wholesalers in the US engaged in sourcing and distributing branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers. Along with Cencora and Cardinal Health, the three account for over 90% of the US pharmaceutical wholesale industry. Outside the US market, McKesson engages in pharmaceutical wholesale and distribution in Canada. Additionally, the company supplies medical-surgical products and equipment to healthcare facilities and provides a variety of technology solutions for pharmacies.
See More
Previous Close:
$828.84
Open:
$834.13
24h Volume:
44,485
Relative Volume:
0.04
Market Cap:
$97.45B
Revenue:
$403.43B
Net Income/Loss:
$5.10B
P/E Ratio:
21.64
EPS:
38.4657
Net Cash Flow:
$5.41B
1W Performance:
+4.70%
1M Performance:
+11.94%
6M Performance:
+2.05%
1Y Performance:
+17.52%
1-Day Range:
$831.63
$840.00
1-Week Range:
$804.12
$861.00
52-Week Range:
$637.00
$999.00
Mckesson Corp Stock (MCK) Company Profile
Name
Mckesson Corp
Sector
Industry
Phone
972-446-4800
Address
6555 STATE HIGHWAY 161, IRVING, TX
Compare MCK vs COR, CAH, HSIC, AHG
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MCK
Mckesson Corp
|
832.33 | 97.35B | 403.43B | 5.10B | 5.41B | 38.47 |
COR
Cencora Inc
|
306.68 | 59.14B | 328.68B | 2.55B | 1.56B | 13.03 |
CAH
Cardinal Health Inc
|
229.06 | 52.87B | 250.74B | 1.55B | 4.39B | 6.5398 |
HSIC
Henry Schein Inc
|
85.19 | 9.82B | 13.38B | 418.00M | 391.00M | 3.3112 |
AHG
Akso Health Group Adr
|
1.60 | 1.35B | 14.85M | -136.07M | 7.25M | -0.4726 |
Mckesson Corp Stock (MCK) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-09-25 | Initiated | Barclays | Overweight |
| Dec-04-24 | Resumed | Mizuho | Neutral |
| Nov-07-24 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Sep-24-24 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Sep-05-24 | Reiterated | Leerink Partners | Outperform |
| Aug-08-24 | Reiterated | Mizuho | Neutral |
| Feb-26-24 | Initiated | Leerink Partners | Outperform |
| Jan-03-24 | Initiated | Barclays | Overweight |
| Dec-14-23 | Initiated | Wells Fargo | Equal Weight |
| Mar-31-23 | Initiated | Citigroup | Buy |
| Aug-22-22 | Resumed | Morgan Stanley | Overweight |
| Jul-06-22 | Downgrade | Argus | Buy → Hold |
| Jun-07-22 | Upgrade | Deutsche Bank | Hold → Buy |
| Apr-01-22 | Resumed | Credit Suisse | Outperform |
| Feb-04-22 | Downgrade | Deutsche Bank | Buy → Hold |
| Jan-07-22 | Upgrade | Credit Suisse | Neutral → Outperform |
| Nov-02-21 | Reiterated | Barclays | Overweight |
| Nov-02-21 | Reiterated | BofA Securities | Buy |
| Nov-02-21 | Reiterated | Evercore ISI | Outperform |
| Nov-02-21 | Reiterated | Jefferies | Buy |
| Mar-30-21 | Upgrade | Argus | Hold → Buy |
| Nov-02-20 | Upgrade | Barclays | Equal Weight → Overweight |
| Aug-04-20 | Upgrade | Deutsche Bank | Hold → Buy |
| May-22-20 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| May-15-20 | Upgrade | UBS | Neutral → Buy |
| Apr-23-20 | Resumed | Credit Suisse | Neutral |
| Mar-18-20 | Upgrade | Goldman | Neutral → Buy |
| Mar-13-20 | Upgrade | Guggenheim | Neutral → Buy |
| Feb-07-20 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Jan-10-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Sep-12-19 | Initiated | Deutsche Bank | Hold |
| Aug-05-19 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Jul-22-19 | Initiated | Guggenheim | Neutral |
| Jan-17-19 | Initiated | UBS | Neutral |
| Oct-26-18 | Reiterated | Barclays | Equal Weight |
| Jul-20-18 | Downgrade | Robert W. Baird | Outperform → Neutral |
| May-29-18 | Reiterated | Leerink Partners | Mkt Perform |
| Mar-08-18 | Initiated | Barclays | Equal Weight |
| Feb-27-18 | Resumed | BofA/Merrill | Buy |
| Feb-02-18 | Reiterated | Mizuho | Neutral |
| Jan-24-18 | Upgrade | Jefferies | Hold → Buy |
View All
Mckesson Corp Stock (MCK) Latest News
McKesson Corp. stock underperforms Monday when compared to competitors - MarketWatch
MCKC Bond Profile — Key Metrics - TradingView
US581557BY0 Bond Profile — Key Metrics - TradingView
McKesson's Q1 2027 Earnings: What to Expect - Barchart.com
McKesson (MCK) Stock Forecast and Price Target 2026 $MCK - MarketBeat
LLY5600584 Bond Profile — Key Metrics - TradingView
A Look at McKesson Corp (MCK) After 5.7% Gain -- GF Value $794.8 - GuruFocus
McKesson Corp. stock outperforms competitors on strong trading day - MarketWatch
LLY5237191 Bond Profile — Key Metrics - TradingView
Jonathan Jackson from Illinois’s 1st district makes trades in Hilton, McKesson, and Sphere Entertainment stocks - Investing.com
Here’s Why McKesson Corporation (MCK) Slid in Q2 - Yahoo Finance
McKesson: Embedding Impact and Purpose Across Operations - Healthcare Digital
XS156717452 Bond Profile — Key Metrics - TradingView
LLY6082068 Bond Profile — Key Metrics - TradingView
McKesson (MCK) Stock Dips While Market Gains: Key Facts - Yahoo Finance
McKesson Corp. stock underperforms Tuesday when compared to competitors - MarketWatch
US581557BC8 Bond Profile — Key Metrics - TradingView
McKesson stock holds steady as healthcare distribution scale anchors long-term appeal - Ad-hoc-news.de
Zacks Industry Outlook McKesson, Cardinal, West Pharmaceutical, Align and Henry - Yahoo Finance
A19WCE Bond Profile — Key Metrics - TradingView
US581557BT1 Bond Profile — Key Metrics - TradingView
McKesson Stock (MCK) Opinions on Political Stock Purchases - Quiver Quantitative
US581557BX2 Bond Profile — Key Metrics - TradingView
McKesson publishes Impact Report with key milestones - HME News
MCK.GL Bond Profile — Key Metrics - TradingView
McKesson (MCK) Falls After CEO Share Sale, Is The 14% Discount Enough? - Yahoo Finance
McKesson stock reflects steady healthcare distribution strength - ad-hoc-news.de
Ritchie John Torres purchases McKesson Corporation stock - Investing.com
McKesson (MCK) Stock Trades Down, Here Is Why - Yahoo Finance
McKesson Corporation's Stock Price Drops to $792.81, Experiencing a 3.16% Decline: An In-depth Analysis - Smartkarma
Is McKesson Corp (MCK) a Bargain After 3.2% Drop? GF Value Says Undervalued - GuruFocus
McKesson Falls as Investors Weigh Recent Leadership Changes and Prior Revenue Concerns - Quiver Quantitative
McKesson Corp. stock underperforms Thursday when compared to competitors - MarketWatch
McKesson's Oncology Leadership and Robust Free Cash Flow Underpin Strong Durable Fundamentals - Morningstar
Congressional Trading Report: Rep. Ritchie Torres Bought Over $1K In McKesson Stock - Benzinga
Brokers Suggest Investing in McKesson (MCK): Read This Before Placing a Bet - Yahoo Finance
Meet the Dallas 500: Brian Tyler, McKesson Corp. - D Magazine
McKesson CEO Brian Tyler sells $6.7 million in company shares - Investing.com
McKesson CEO Brian Tyler sells $6.7 million in company shares By Investing.com - Investing.com Nigeria
Form 4 McKesson For: 8 July By Investing.com - Investing.com Canada
McKesson (MCK) CEO’s 8,463-share sale executed under Rule 10b5-1 plan - Stock Titan
McKesson Checks All The Boxes To Survive And Prosper In A Weak Economy, But There's A Big Catch - Seeking Alpha
McKesson Corporation (MCK) is Attracting Investor Attention: Here is What You Should Know - Yahoo Finance
McKesson wound care portfoliodiscreet dressings for home patients - ad-hoc-news.de
McKesson (MCK) Increases Despite Market Slip: Here's What You Need to Know - Yahoo Finance
Form 144 MCKESSON CORP For: 7 July By Investing.com - Investing.com Nigeria
McK (NYSE: MCK) Form 144 shows Brian S. Tyler plans to sell shares - Stock Titan
Eli Lilly and vs. Teva: Which Pharmaceutical Stock Is a Better Buy in 2026? - The Motley Fool
Will McKesson (MCK) Beat Estimates Again in Its Next Earnings Report? - Yahoo Finance
McKesson posts Q1 earnings beat, but revenue misses estimates; Shares fall 2% - Investing.com
McKesson: The Healthcare Supplier On My Buy List This Summer, As Growth Accelerates (NYSE:MCK) - Seeking Alpha
Mckesson Corp Stock (MCK) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.01%
0.20%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):